Does Affinity Health Plan Cover Adderall?

Understanding Affinity Health Plan's Current Status

Affinity Health Plan was a Bronx-based nonprofit Medicaid managed care organization that served members across New York City's five boroughs. Molina Healthcare acquired Affinity in 2014, and the plan now operates under the Molina Healthcare of New York banner. If your insurance card still reads "Affinity Health Plan," your coverage is administered by Molina.

This matters for formulary lookups. Searching the Affinity name on pharmacy databases will return outdated results. You need to check Molina Healthcare of New York's current Medicaid formulary, which is updated quarterly, to verify whether a specific drug and formulation are covered. Molina's Medicaid formulary in New York follows the state's Medicaid Preferred Drug List (PDL) as a baseline, with plan-specific additions and restrictions layered on top. New York's PDL committee reviews stimulant medications annually, and the FDA-approved prescribing information for mixed amphetamine salts serves as the clinical foundation for coverage criteria [1]. The state requires all Medicaid managed care plans, including Molina/Affinity, to cover at least one medication in each therapeutic class.

Short version: your old Affinity plan likely does cover a form of Adderall. The details depend on which formulation, whether you are using a generic, and whether your prescriber completes the required paperwork.

Generic Mixed Amphetamine Salts vs. Brand-Name Adderall

The distinction between generic and brand drives most coverage decisions for this medication. Generic mixed amphetamine salts (immediate-release) have been available since 2002, and the FDA considers them therapeutically equivalent to brand-name Adderall [2]. These generics cost Medicaid programs roughly $0.30 to $0.80 per tablet, compared to brand-name pricing that can exceed $10 per tablet.

For Medicaid managed care plans in New York, generic IR amphetamine salts sit on the preferred tier. That means no prior authorization for most adults aged 18 and older with a documented ADHD diagnosis. Copays for Medicaid members are capped by federal law. Most members pay $0 to $3 per prescription.

Brand-name Adderall is a different story. Because a clinically equivalent generic exists, Molina/Affinity can require prior authorization before covering the brand product. Your prescriber would need to document a clinical reason why the generic is not appropriate, such as an allergy to an inactive ingredient in the generic formulation or a documented therapeutic failure. A 2019 review in the Journal of the American Academy of Child and Adolescent Psychiatry found that generic and brand stimulant formulations produced comparable symptom reduction on standardized ADHD rating scales in 94% of patients studied [3].

Adderall XR and Extended-Release Coverage

Extended-release formulations add another layer of complexity. Adderall XR (mixed amphetamine salts extended-release capsules) provides a biphasic release profile, delivering roughly half the dose immediately and the other half about four hours later. The American Academy of Pediatrics 2019 clinical practice guideline notes that extended-release stimulants are preferred for school-age children because they reduce the need for a midday dose and improve medication adherence [4].

Molina's New York Medicaid formulary typically covers at least one extended-release amphetamine product, but step therapy requirements are common. Step therapy means your prescriber must first try you on an immediate-release generic stimulant. If the IR formulation causes problems (wearing off too early, rebound symptoms, adherence difficulties), the prescriber documents this and requests authorization for Adderall XR or its generic equivalent.

Generic extended-release mixed amphetamine salts have been available since 2009. Coverage for these generics is generally more favorable than for brand Adderall XR. A study published in Pediatrics (N=230) found that extended-release stimulants improved classroom behavior ratings by 1.6 standard deviations compared to placebo, supporting the clinical rationale for ER formulations when IR versions prove inadequate [5].

The Prior Authorization Process Step by Step

Prior authorization for stimulants under Molina/Affinity follows a predictable sequence. Your prescriber submits a request to the plan's pharmacy benefit manager, including the diagnosis code (F90.0, F90.1, or F90.2 for ADHD), documentation of symptom severity, and, if step therapy applies, evidence that a preferred alternative was tried.

New York State Medicaid regulations require plans to process standard prior authorization requests within 72 hours and urgent requests within 24 hours. If the plan does not respond within these windows, state law requires a 72-hour emergency supply to be dispensed at the pharmacy. The Centers for Medicare and Medicaid Services mandates that all state Medicaid programs maintain drug utilization review programs that balance access with appropriate prescribing safeguards for Schedule II controlled substances [6].

Common reasons for denial include missing documentation of the ADHD diagnosis, no record of a trial with a preferred formulary alternative, or requesting a quantity that exceeds the plan's quantity limits. For adults, most plans cap Adderall IR at 60 tablets per 30 days (representing a twice-daily dosing schedule). For Adderall XR, 30 capsules per month is standard. Your prescriber can request a quantity exception if clinically warranted.

A practical tip: ask your prescriber's office to include the specific rating scale scores (such as the Adult ADHD Self-Report Scale or the Vanderbilt Assessment) in the prior authorization request. Plans approve requests with objective clinical data at higher rates than those with narrative-only justifications.

What Adderall Costs Under Affinity/Molina Medicaid

Federal Medicaid rules set maximum copayment thresholds for prescription drugs. For preferred generic drugs, most Medicaid members pay $1 to $3 per prescription. Some categories of Medicaid beneficiaries, including children under 18 and pregnant women, are exempt from all copayments.

If your prescriber obtains approval for brand-name Adderall or Adderall XR, the non-preferred brand copay is typically $3, though this varies based on your specific Medicaid eligibility category. The Medicaid and CHIP Payment and Access Commission reported that stimulant medication costs account for approximately $2.8 billion annually across state Medicaid programs, with generic utilization rates exceeding 85% nationally [7].

If you have Molina through a Marketplace (exchange) plan rather than Medicaid, your cost structure is different. Exchange plans use tiered formularies with percentage-based coinsurance. Generic Adderall IR might fall on Tier 1 ($10 to $15 copay), while Adderall XR could land on Tier 2 or Tier 3 ($30 to $75 copay). Check your specific plan's Summary of Benefits and Coverage document for exact tier placement.

ADHD Medications Covered as Alternatives

If Adderall or its generic is not approved, or if side effects make it a poor fit, Molina/Affinity's formulary includes several alternatives. Knowing these options strengthens your position in discussions with your prescriber and during any appeal process.

Methylphenidate immediate-release (generic Ritalin) is the most commonly prescribed first-line stimulant on Medicaid formularies nationwide. The National Institute of Mental Health notes that stimulant medications, including both amphetamine and methylphenidate classes, show effect sizes between 0.8 and 1.0 for core ADHD symptom reduction [8]. A Cochrane systematic review of 185 randomized controlled trials (N=12,245) found no consistent superiority of amphetamine-based stimulants over methylphenidate-based stimulants for ADHD symptom control in adults [9], as reported in the Cochrane Database of Systematic Reviews.

Lisdexamfetamine (Vyvanse) became available as a generic in 2023. Because lisdexamfetamine is a prodrug that requires enzymatic conversion in the body, it has a lower abuse potential profile than immediate-release amphetamine salts. Molina may cover generic lisdexamfetamine with prior authorization. Atomoxetine (generic Strattera), a non-stimulant option, is typically covered without prior authorization and may be required as a step-therapy prerequisite for stimulant approval in some plan configurations.

Guanfacine extended-release (generic Intuniv) and clonidine extended-release (generic Kapvay) are alpha-2 agonists approved for pediatric ADHD. These appear on most Medicaid formularies as adjunctive therapies, though their effect sizes for core ADHD symptoms (0.4 to 0.6) are smaller than those of stimulants, according to a meta-analysis in the Journal of the American Medical Association [10].

How to Appeal a Coverage Denial

A denial is not the final answer. New York Medicaid members have clearly defined appeal rights. The first step is an internal appeal, which must be filed within 60 days of the denial notice. Molina must decide your internal appeal within 30 days for a standard request or 72 hours for an expedited appeal involving urgent medical need.

Your appeal should include a letter from your prescriber explaining why the denied medication is medically necessary and why alternatives are clinically inappropriate. Include objective clinical documentation: standardized ADHD rating scale scores, a history of medications tried and the specific reasons each was discontinued, and any relevant lab work or neuropsychological testing results.

If the internal appeal is denied, you can request an external review through the New York State Department of Financial Services. An independent clinical reviewer, not employed by Molina, evaluates your case. The Agency for Healthcare Research and Quality recommends that patients keep copies of all prior authorization submissions, denial letters, and clinical documentation to support external appeals [11].

For Medicaid members specifically, you also have the right to a Fair Hearing through the New York State Office of Temporary and Disability Assistance. Fair Hearings are administrative proceedings where an independent judge reviews the plan's decision. Requesting a Fair Hearing within 10 days of the denial can preserve your existing benefits (called "aid continuing") if you were previously receiving the medication.

Special Considerations for Children and Adolescents

Prescribing stimulants to children under 6 requires additional scrutiny under Molina/Affinity's protocols. The American Academy of Pediatrics recommends behavior therapy as the first-line treatment for preschool-age children with ADHD, with medication reserved for cases where behavioral interventions prove insufficient [4]. Molina typically requires documentation that behavioral therapy was attempted before approving any stimulant for a child aged 3 to 5.

For children aged 6 to 17, stimulant prescriptions follow standard formulary rules, but New York's Medicaid program mandates additional monitoring. Prescribers must document baseline height, weight, blood pressure, and heart rate before starting stimulants. Follow-up visits are expected every 30 days during dose titration and at least every three months once a stable dose is reached. The CDC reports that approximately 9.8% of U.S. children aged 3 to 17 (about 6 million) have received an ADHD diagnosis, with medication treatment rates varying from 62% in some states to 77% in others [12].

New York Medicaid also participates in the HEDIS ADHD medication management measures, which track whether children newly prescribed ADHD medications receive appropriate follow-up care. Plans that score poorly on these measures face financial penalties, creating an incentive for Molina to ensure timely access to prescribed stimulants rather than creating excessive prior authorization barriers.

Filling Your Prescription: Pharmacy Network Considerations

Molina Healthcare of New York contracts with a broad pharmacy network, including most chain pharmacies (CVS, Walgreens, Rite Aid, Duane Reade) and many independent pharmacies across the five boroughs. However, Adderall and its generics are Schedule II controlled substances under DEA regulations, which means they cannot be called in or faxed to a pharmacy in most circumstances [13]. Your prescriber must issue an electronic prescription through an approved e-prescribing system or, in limited cases, provide a written prescription on tamper-resistant paper.

Schedule II prescriptions have no refills. Each month requires a new prescription. Some prescribers write post-dated prescriptions (up to three at a time, each covering a 30-day supply) to reduce the administrative burden of monthly office visits, a practice permitted under New York State law with certain restrictions.

If your pharmacy reports that generic mixed amphetamine salts are out of stock, this may reflect ongoing supply constraints that the FDA first acknowledged in October 2022. Ask your pharmacist to check availability at other locations within the Molina network, or contact Molina's pharmacy help line to locate a nearby pharmacy with stock. Supply has improved significantly since 2024, but intermittent regional shortages still occur with specific manufacturers and dosage strengths.